Kallyope, Inc., a NYC-based biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, closed a $236m Series D financing.
The round was co-led by Mubadala Investment Company and The Column Group, with participation from previous investors Alexandria Venture Investments, Bill Gates, Casdin Capital, Euclidean Capital, Illumina Ventures, Lux Capital, Polaris Partners, Two Sigma Ventures and StepStone Group and new investors DNS Capital, Hartford Healthcare Endowment, Parkwood LLC, and Tao Capital.
The funds will be used to advance the company’s drug discovery platform, clinical trials, and pipeline of multiple programs across a broad range of therapeutic areas.
Led by Jay Galeota, president and CEO, and Nancy Thornberry, founding CEO and chair, Research and Development, Kallyope provides a platform that integrates several technologies for the discovery and translation of gut-brain biology. By revealing the connections between the gut and the brain, the platform has been leveraged to generate novel programs spanning several relevant therapeutic areas, including metabolism, immunology and inflammation, and central nervous system disorders.
Over the past 13 months, Kallyope has advanced four compounds into the clinic in its two lead programs in Type 2 diabetes, obesity, and diseases of the gastrointestinal barrier.
The company’s founders are Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D., and Nobel laureate Richard Axel, M.D.
FinSMEs
15/02/2022